Recent Posts

Pages: 1 [2] 3 4 ... 10
11

From JAMA Neurology (June 11, 2019), a report on a large Swedish study, "Changes in the risk of reaching MS disability milestones in recent decades: A nationwide population-based cohort study in Sweden":

http://bit.ly/2KIRkgq


Quote
Conclusions and Relevance

Risk of reaching major disability milestones has significantly decreased over the last decade in patients with relapsing-onset MS in Sweden. Several factors could potentially be responsible for this observation. However, given that no change was seen in disability accrual of patients with progressive-onset MS and the absence of efficacious treatment option in this group, increased use of more efficacious disease-modifying treatments could be a possible driver of this change.
12
MISCELLANEOUS / Why don't whales develop cancer?
« Last post by agate on June 10, 2019, 09:00:46 pm »
From Medical News Today (May 15, 2019), an article reporting that whales (as well as elephants) have an astoundingly low rate of cancer--"Why Don't Whales Develop Cancer, and Why Should We Care?"


http://bit.ly/2ZfJoaz




13
The PSAPs now being marketed are apparently just as good as the far more expensive hearing aids, but only if your hearing loss is mild to moderate, according to this article abstracted from JAMA Otolaryngology (May 16, 2019), "Clinical Performance Evaluation of a Personal Sound Amplification Product as a Basic Hearing Aid and a Premium Hearing Aid":


http://bit.ly/2R1f1BD
14
Not much information about just how the patients taking Tysabri (or other MS drugs) are doing over time but this research concludes:


Quote
When taking into account early inflammation and the impact of natalizumab on disease activity during the initial treatment phase, a higher than expected proportion of patients showed disability progression.


From PubMed, June 8, 2019--"Long-term disease activity and disability progression in RRMS patients on natalizumab" by researchers in Amsterdam, including two who are well known in MS research--Barkhof, Uitdehaag:


https://www.ncbi.nlm.nih.gov/pubmed/31174043
15
GENERAL DISCUSSION - RESEARCH, NEWS / Red meat to reduce risk of MS?
« Last post by agate on June 07, 2019, 08:01:30 pm »

Someone has come up with the idea that eating red meat reduces the risk of MS. This article discusses the idea but ends with this statement:


Quote

[/color]However, not all agree that red meat has links to health benefits. Indeed, the World Health Organization (WHO) classified red meat as "probably carcinogenic" to humans in 2015.
[/color]Earlier this year, researchers found that people who ate small amounts of unprocessed red meat, amounting to 65 g or less per day, had a moderately higher risk of death.
[/color]Dietary choices are complex and include personal preferences, cultural influences, and socioeconomic factors. There is plenty of evidence that links a healthful diet to long-term health outcomes. How prominently unprocessed red meat will feature in the prevention of MS remains to be seen.
[/color]

http://bit.ly/2I4DIdT
16
From Science Daily, "Scientists edge closer to root causes of multiple sclerosis" (June 6, 2019):


http://bit.ly/2Xv699V
17
This is an excellent article from the New York Times (June 5, 2019), "Protecting Sleep in the Hospital, for Both Patients and Doctors" by Amitha Kalaichandran, MD:

http://bit.ly/ProtectingSleepintheHospital
18
The abstracts from the recent AAN conference included quite a large number on the topic of serum neurofilament light chains as a biomarker for MS. This brief article and comment from NEJM Journal Watch (June 4, 2019) tells a little about them:


[/size]SUMMARY AND COMMENT | NEUROLOGYJune 4, 2019
[/size]Serum Neurofilament Light Chain as a Prognostic Marker in Multiple Sclerosis
[/size][/b][/font][/color][/font][/size][/t][/color][/font]
[/size]Robert T. Naismith, MD reviewing Kuhle J et al. Neurology 2019 Mar 5[/size]Patients with high NfL levels had increased risk for worse disease outcomes.Neurofilament light chain (NfL) in serum and cerebrospinal fluid is an indicator of axonal injury associated with multiple sclerosis (MS). To evaluate this molecule as a prognostic biomarker, investigators measured serum NfL in patients with relapsing-remitting MS enrolled in two phase III studies of fingolimod. In the FREEDOMS study, 269 participants received fingolimod or placebo for 24 months; in the TRANSFORMS study, 320 participants received fingolimod or interferon β-1a for 12 months.
Compared with 35 healthy controls (HC), patients with MS had higher baseline serum NfL (30.5 pg/mL [FREEDOMS], 27.0 pg/mL [TRANSFORMS], 16.9 pg/mL [HC]). High baseline NfL levels were positively associated with high volume of T2-weighted lesions as well as presence of gadolinium-enhancing (Gd+) lesions. Among patients with Gd+ lesions, NfL levels were 64% higher (FREEDOMS) and 48% higher (TRANSFORMS) than among patients without Gd+ lesions. At 6 months, NfL concentrations fell from baseline by 35% (FREEDOMS) and 36% (TRANSFORMS). Compared with patients who had baseline NfL levels <30 pg/mL, those with NfL concentrations >60 pg/mL were 2.6 times more likely to have a new or enlarging T2 lesion and 2.5 times more likely to have a relapse; they also had 2.9 times greater loss of brain volume and 1.9 times higher risk for worsening disability.
[/font]
[/size]
[/size]COMMENTAs a reflection of axonal damage, NfL is a promising biomarker for monitoring disease activity and progression in MS. This analysis confirms that NfL levels are elevated in patients with MS and diminish with treatment; moreover, baseline NfL levels predict risk for relapse, disability, new lesions, and brain atrophy. NfL is now an important tool in many MS trials and it may someday become a core prognostic gauge to complement the existing clinical and imaging measures.[/t][/t]
[/size][/font][/font][/color][/font]
19
TREATMENTS / About Mavenclad and Mayzent in Canada
« Last post by agate on June 03, 2019, 07:38:56 pm »
From Multiple Sclerosis News Today (June 3, 2019), the second half of this article indicates that in Canada, Mayzent (siponimod) might be available for patients with non-active SPMS--"Mavenclad May Surpass Gilenya as DMT of Choice for MS in Canada":


http://bit.ly/2WiRNgm
20
From Medical News Today (June 2, 2019)--"How Cranberries May Curb the Antibiotic-Resistance Crisis":


http://bit.ly/2wz8IvP
Pages: 1 [2] 3 4 ... 10